21 |
Mechanisms of Follicular Thyroid Cancer Development and Progression in the Context of Dysregulated PKAPringle, Daphne R. 13 September 2013 (has links)
No description available.
|
22 |
Preclinical Modeling of Musculoskeletal CancerChaffee, Beth K. January 2013 (has links)
No description available.
|
23 |
Intestinal Dysfunction in Cystic FibrosisVitko, Megan Sue 01 June 2016 (has links)
No description available.
|
24 |
GROWTH HORMONE (GH) INFLUENCES ADIPOCYTE SIZE IN MOUSE MODELS WITH VARYING LEVELS OF GH SIGNALINGLi, Aiyun 29 December 2006 (has links)
No description available.
|
25 |
Pathological and molecular profiling in hypertension-induced glomerular injuryBelghasem, Mostafa E. 03 November 2015 (has links)
The increased prevalence of chronic kidney disease (CKD) has become a major global health burden. This increase in CKD burden parallels the increase in hypertension prevalence. In addition, increasing evidence suggest that genetics play a strong role in the susceptibility for renal disease. Inbred mouse strains C57BL/6 and 129S6SvEv differ in their susceptibility to kidney disease when subjected to hypertension using the DOCA/salt uninephrectomy model of hypertension. Similar to others, we found the 129S6SvEv mice to be susceptible to develop severe glomerulosclerosis, whereas the C57BL/6 mice are comparatively resistant. To identify new candidate genes that are involved in the pathogenesis of glomerular disease, we used microarray technology to compare the glomerular transcriptome of both strains and determine changes in glomerular gene expression when subjected to the DOCA/salt uninephrectomy model of systemic hypertension. This approach was accompanied with ultrastructural analysis and glomerular stiffness measurements to identify corresponding structural changes. Here, we have identified novel genes associated with strain differences and hypertension, and we used immunohistochemistry to validate their expression in podocytes and glomerular arterioles in murine and human kidneys. The increased understanding of the molecular mechanisms underlying hypertension-associated podocyte injury and glomerular damage which will result from these studies, will ultimately lead to identification of novel pharmacologic targets or therapeutic strategies for patients with hypertension and renal disease. / 2017-11-02T00:00:00Z
|
26 |
Mechanisms by which p53 Regulates Radiation-induced Carcinogenesis and Myocardial InjuryLee, Chang-Lung January 2012 (has links)
<p>Radiation therapy can cause acute toxicity and long-term side effects in normal tissues. Because part of the acute toxicity of radiation is due to p53-mediated apoptosis, blocking p53 during irradiation can protect some normal tissues from acute radiation injury and might improve the therapeutic ratio of radiation therapy. However, the mechanisms by which p53 regulates late effects of radiation are not well understood. Here, I utilized genetically engineered mouse models to dissect the role of p53 in regulating two of the most clinically significant late effects of radiation: radiation-induced carcinogenesis and radiation-induced myocardial injury. </p><p> It has been well characterized that mice with one allele of p53 permanently deleted are sensitized to radiation-induced cancer. Therefore, temporary inhibition of blocking p53 during irradiation could promote malignant transformation. Experiments with mice lacking functional p53 in which p53 protein can be temporarily restored during total-body irradiation (TBI) suggest that the radiation-induced p53 response does not contribute to p53-mediated tumor suppression. Here, I performed reciprocal experiments and temporarily turned p53 off during TBI using transgenic mice with reversible RNA interference against p53. I found that temporary knockdown of p53 during TBI not only ameliorated acute hematopoietic toxicity, but in both Kras wild-type and tumor-prone KrasLA1 mice also prevented lymphoma development. Mechanistic studies show that p53 knockdown during TBI improves survival of hematopoietic stem and progenitor cells (HSPCs), which maintains HSPC quiescence and prevents accelerated repopulation of surviving cells. Moreover, using an in vivo competition assay I found that temporary knockdown of p53 during TBI maintains the fitness of p53 wild-type HSPCs to prevent the expansion of irradiated mutant cells. Taken together, our data demonstrate that p53 functions during TBI to promote lymphoma formation by facilitating the expansion of irradiated HSPCs with adaptive mutations. </p><p> p53 functions in the heart to promote myocardial injury after multiple types of stress, including ischemic injury, pressure overload and doxorubicin-induced oxidative stress. However, how p53 regulates radiation-induced myocardial injury, which develops after radiation therapy, is not well understood. Here, I utilized the Cre-loxP system to demonstrate that p53 functions in endothelial cells to protect mice from myocardial injury after a single dose of 12 Gy or 10 daily fractions of 3 Gy whole-heart irradiation (WHI). Mice in which both alleles of p53 are deleted in endothelial cells succumbed to heart failure after WHI due to myocardial necrosis, systolic dysfunction and cardiac hypertrophy. Moreover, the onset of cardiac dysfunction was preceded by alterations in myocardial vascular permeability and density. Mechanistic studies using primary cardiac endothelial cells (CECs) irradiated in vitro indicate that p53 signals to cause a mitotic arrest and protects CECs against radiation-induced mitotic catastrophe. Furthermore, mice lacking the cyclin-dependent kinase inhibitor p21, which is a transcriptional target of p53, are also sensitized to myocardial injury after 12 Gy WHI. Together, our results demonstrate that the p53/p21 axis functions to prevent radiation-induced myocardial injury in mice. Our findings raise the possibility that when combining radiation therapy with inhibitors of p53 or other components of the DNA damage response that regulate mitotic arrest, patients may experience increased radiation-related heart disease. </p><p> Taken together, our results demonstrate crucial but distinct roles of p53 in regulating late effects of radiation: p53-mediated apoptosis promotes radiation-induced lymphomagenesis, but p53-mediated cell cycle arrest prevents radiation-induced myocardial injury. These findings indicate that p53 may generally play a protective role from radiation, particularly at high doses, in cells where p53 activation is uncoupled from the induction of the intrinsic pathway of apoptosis. Therefore, selectively inhibiting p53-mediated apoptosis may be a promising approach to ameliorate acute radiation toxicity without exacerbating late effects of radiation.</p> / Dissertation
|
27 |
Cellular and subcellular analysis of peripheral neuropathy caused by peroxisomal dysfunction in miceKleinecke, Sandra 04 October 2016 (has links)
No description available.
|
28 |
Avaliação do padrão de degeneração e regeneração muscular em diferentes modelos murinos para distrofias musculares progressivas / Study of degeneration and regeneration pathways, in mice models for muscular dystrophiesOliveira, Paula Cristina Gorgueira Onofre 22 April 2009 (has links)
As distrofias musculares constituem um grupo heterogêneo de doenças caracterizadas por uma degeneração progressiva e irreversível da musculatura esquelética. A fraqueza muscular se manifesta quanto existe um desequilíbrio entre os ciclos de degeneração e regeneração, com subseqüente substituição por tecido conjuntivo e adiposo das fibras musculares eliminadas. Diversos fatores estão implicados nestes processos, e as vias de atuação de cada um deles ainda não são totalmente conhecidas. Os mais importantes marcadores da via miogênica são os fatores Myf5, MyoD, Myf6 e miogenina. Os marcadores da degeneração, por sua vez, são o TGFβ-1, citocina inflamatória provavelmente envolvida no processo de fibrose do músculo distrófico, e o aumento da expressão do próprio colágeno, componente da matriz extracelular. O objetivo do presente projeto consistiu em estudar os fatores relacionados com as vias de degeneração e regeneração em modelos murinos distróficos com diferentes defeitos nas proteínas musculares, para elucidação dos mecanismos fisiopatológicos envolvidos, visando terapias. Para tal, foram estabelecidas três abordagens: 1-) Estudar o potencial terapêutico de células-tronco mesenquimais de medulas óssea, nos modelos Lama2dy-2J/J (deficiente para a proteína α2-laminina) e Largemyd (defeito de glicosilação); 2-) Estudar a expressão relativa dos genes envolvidos nas vias de degeneração e regeneração nos diferentes modelos murinos para distrofias musculares; 3-) Estudar o papel da distrofina e α2-laminina na organização do complexo distrofina-glicoproteínas associadas no músculo esquelético, através da produção de um camundongo duplo-mutante deficiente para estas duas proteínas. Na primeira abordagem, células-tronco mesenquimais de medula, expressando a proteína eGFP, foram injetadas por via sistêmica em camundongos Lama2dy-2J/J e Largemyd, mas não foram localizadas posteriormente no músculo dos animais testados. Testes complementares mostraram que células MSC e C2C12 expressando eGFP permanecem por curtos períodos de tempo no tecido injetado, sugerindo que são eliminadas do músculo distrófico em virtude da expressão permanente de eGFP. Análise funcional realizada nestes animais mostrou uma grande heterogeneidade de resposta nos diversos testes aplicados, compatível com a variabilidade clínica também observada em pacientes humanos. Na segunda abordagem, analisamos a expressão dos genes da cascata de degeneração e regeneração nos modelos distróficos mdx, SJL/J, Lama2dy-2J/J e Largemyd, e correlacionamos estes resultados com o padrão histopatológico de cada modelo. Os resultados observados sugerem que o gene TGFβ-1 é ativado pelo processo distrófico em qualquer grau de degeneração, enquanto a ativação da expressão do gene PCOL possivelmente ocorre nos estágios iniciais deste processo. Observou-se também que cada mecanismo patofisiológico atuou de forma diversa na ativação da regeneração, com diferenças na indução da proliferação das células-satélite, mas sem alterações no estimulo à diferenciação. Assim, a disfunção na população de células-satélite pode representar um mecanismo importante na patogênese das distrofias musculares. Na terceira abordagem, um modelo murino duplo-mutante para as proteínas distrofina e α2-laminina foi gerado a partir de cruzamentos das linhagens mdx e Lama2dy-2J/J, com a proporção mendeliana esperada, sendo, portanto, viável. O animal duplo-afetado está apresentando fraqueza muscular mais acentuada que os modelos parentais. Estudos complementares de proteínas musculares serão ainda realizados neste novo modelo para verificar a presença ou não das demais proteínas do DGC e sua relação com o padrão de degeneração/regeneração muscular. / The muscular dystrophies are a heterogeneous group of genetic diseases characterized by progressive and irreversible degeneration of skeletal muscles. Muscle weakness is the consequence of an imbalance between successive cycles of degeneration and regeneration, with further replacement of the degraded muscle fibers by adipose and connective tissues. Several factors are involved these processes and the respective functional pathways are still not well known. Myf5, MyoD, Myf6 and myogenin are important factors responsible for the myogenesis and regeneration in the muscle. One important marker for the degeneration is TGF-1, which is an inflammatory cytokine with a possible role in the stimulation of fibrosis in the dystrophic muscle through the activation of genes related to the expression of collagen. The main objective of this project was to study the factors involved in the degeneration and regeneration pathways, in mice models for muscular dystrophies, carrying different defects in muscle proteins, to better understand the involved pathophysiological mechanisms, aiming future therapies. This was done through three strategies: 1-) The study of the therapeutic potential of transplantation of bone marrow mesenchymal-eGFP transformed stem cells, in Lama2dy-2J/J (a2 laminin deficient mice) and Largemyd (mice with defect in the glycosilation of -DG) ; 2-) The analyses of the relative expression of genes involved in regeneration and degeneration, in different mice models for muscular dystrophies; 3-) The study of the roles of dystrophin and 2-laminin proteins in the organization of the dystrophin-glycoprotein complex in muscle sarcolemma through the generation of a new mouse model, double-mutant for these two proteins. In the first approach, bone marrow mesenchymal stem cells expressing eGFP protein were intravenously injected in Lama2dy-2J/J and Largemyd mice, but these cells were not localized in the muscle of the tested animals after 3 months of experiment. Complementary studies showed that MSC and C2C12 cells expressing eGFP, when directly injected in the muscle of these models, were retained for only a few days, suggesting a rejection against cells expressing eGFP in the dystrophic muscle. Functional analysis showed a high variability among the tested mice, which is similar to the significant clinical variability observed in human patients with muscular dystrophies. In the second approach we quantified the expression of genes involved in degeneration and regeneration pathways in the dystrophic models mdx, SJL/J, Lama2dy-2J/J and Largemyd, and correlated these data with muscle histopathological pattern of each model. The result suggests that TGFβ-1 gene is activated in the dystrophic process in all the stages of degeneration while the activation of the expression of the PCOL gene possibly occurs in earliest stages of this process. We also observed that each physiopathological mechanism acted differently in the activation of regeneration, with differences in the induction of proliferation of satellite cells, but with no alterations in stimulation to differentiation. Dysfunction of satellite cells can therefore be an important additional mechanism of pathogenesis in the dystrophic muscle. In the third approach we generated a new dystrophic mouse model, carrying two simultaneous deficiencies of the proteins dystrophin and 2-laminin, by crossing mdx and Lama2dy-2J/J strains. In the offspring, the proportion of affected double-mutant mice was within the expected mendelian proportion, showing therefore, the viability of these defects with life. Only 4 alive animals were obtained up to the present date, and they are being followed for clinical characterization. The phenotype of this double-mutant mouse is very severe, presenting significant weakness, starting earlier and progressing faster that the parental strains. When more affected animals will be available, additional protein studies will be done to verify the effect of these two deficiencies in the organization of the DGC complex and its effect on the cascades of muscle degeneration and regeneration.
|
29 |
Non-invasive evaluation of murine models for genetic muscle diseases / Evaluation atraumatique de modèles murins de maladies musculaires génétiquesMartins Bach, Aurea Beatriz 12 May 2015 (has links)
De nouvelles options thérapeutiques sont en cours d'introduction pour les maladies musculaires génétiques telles que les dystrophies musculaires et les myopathies congénitales, maladies jusque là sans traitement causal. Ces développements récents ont suscité un intérêt renouvelé et croissant pour les méthodes atraumatiques en vue de caractériser et de suivre les muscles atteints, en particulier pendant et après une intervention thérapeutique. Dans ce contexte, les modèles animaux sont essentiels pour mieux comprendre les mécanismes des maladies et pour tester des nouvelles thérapies. Récemment, il y a eu des avancées significatives dans l'évaluation atraumatique de modèles murins de maladies musculaires génétiques. Néanmoins, nombre de lignées de souris n'ont pas encore été caractérisées de façon atraumatique et il reste à mettre au point des méthodes plus sensibles pour identifier précocement des altérations subtiles dans le muscle des souris malades. L'objectif de cette thèse est d'appliquer des techniques atraumatiques innovantes à l'étude du muscle de modèles murins de maladies musculaires génétiques avec des phénotypes variés. Trois lignées de souris modèles de dystrophies musculaires (mdx, Large_myd et mdx/Large_myd) et une lignée de souris modèle de la myopathie congénitale (KI-Dnm2_R465W) ont été étudiées par des méthodes de Résonance Magnétique Nucléaire (RMN). Deux lignées dystrophiques (Large_myd et mdx/Large_myd) plus des souris normales après une blessure ont été étudiées par micro-tomographie (micro-CT). En RMN, toutes les souches de souris affectées ont présenté un T2 musculaire augmenté, en relation avec une gamme d'anomalies histologiques, y comprises nécrose et inflammation, mais aussi des groupes de fibres en régénération ou des fibres avec altérations de l'architecture. Avec la combinaison de la RMN et de l'analyse de la texture, il a été possible d'identifier sans ambiguïté toutes les lignées dystrophiques, alors que la seule mesure du T2 ne permettait pas de les différencier. Les souris mdx ont présenté des altérations fonctionnelles et morphologiques du réseau vasculaire musculaire. Pour les souris KI-Dnm2_R465W, des études préliminaires ont révélé une tendance à développer des altérations fonctionnelles musculaires. Finalement, les images de micro-CT n'ont pas pu détecter des différences du contenu musculaire dans les souris dystrophiques. L'ensemble des résultats non seulement enrichit le panel de modèles murins de maladies génétiques musculaires caractérisés de manière atraumatique, il révèle également un certain degré de spécificité des anomalies dans l'imagerie, comme l'a montré l'analyse de texture. Les résultats démontrent aussi que des méthodes de RMN non-invasives peuvent être assez sensibles pour identifier des altérations subtiles dans le phénotype musculaire murin, même à des stades précoces. Cette thèse a été développée dans le cadre d'une co-tutelle internationale entre la France et le Brésil, et elle a comporté un important transfert de compétence, qui a permis de réaliser les premières explorations atraumatiques du muscle murin effectuées au Brésil. / Novel therapeutic approaches are being introduced for genetic muscle diseases such as muscle dystrophies and congenital myopathies, all of them having remained without cure so far. These recent developments have motivated a renewed and augmented interest in non-invasive methods for muscle characterization and monitoring, particularly during and after therapeutic intervention. In this context, animal models are essential to better understand the disease mechanisms and to test new therapies. Recently, significant advances in the non-invasive evaluation of mouse models for genetic muscle diseases have been achieved. Nevertheless, there were still several mouse strains not characterized non-invasively, and it was necessary to develop sensitive methods to identify subtle alterations in the murine affected muscle. The purpose of this thesis was to apply non-invasive techniques in the study of murine models for genetic muscle diseases with variable phenotypes. Three mouse models for muscle dystrophy (mdx, Large_myd, mdx/Large_myd) and one mouse model for congenital myopathy (KI-Dnm2_R465W) were studied with Nuclear Magnetic Resonance (NMR) methods. Two dystrophic strains (Large_myd, mdx/Large_myd) and normal mice after injury were studied through micro-Computed Tomography (micro-CT). On NMR, all affected mouse strains presented increased muscle T2, which could be related to variable features in the histological evaluation, including necrosis and inflammation, but also to clusters of fibers under regeneration or with altered cytoarchitecture. The combination of NMR and texture analyses allowed the unambiguous differential identification of all the dystrophic strains, although it was not feasible when comparing the muscle T2 measurements only. Mdx mice showed functional and morphological alterations of vascular network. In the KI-Dnm2_R465W mice, a pilot study revealed tendencies of functional impairment. Finally, micro-CT images were unable to detect differences in muscle´s content in dystrophic mice. Altogether, these results not only increased the number of murine models for genetic muscle diseases non-invasively characterized, it also demonstrated some degree of specificity of the imaging anomalies, as revealed by texture analysis. It also showed that non-invasive NMR methods can be sensitive enough to identify subtle alterations in murine muscle phenotype, even in early stages. This thesis was developed under an international joint supervision between France and Brazil, and comprised an important transfer of technology, with the first non-invasive studies of murine muscles performed in Brazil.
|
30 |
Etude fonctionnelle de l'inactivation de TET2 au cours de l'hématopoïèse chez la souris / Role of Tet2 inactivation in mouse hematopoiesisQuivoron, Cyril 19 September 2012 (has links)
Des mutations acquises du gène TET2 ont été décrites dans les hémopathies malignes humaines. La fréquence de ces anomalies dans les hémopathies myéloïdes est de 10 à 20%, atteignant 50% dans les échantillons de leucémies myélo-monocytaires chroniques (LMMC). Les mutations observées sont inactivatrices, ce qui suggère que TET2 est un gène de type suppresseur de tumeur et que les mutations retrouvées conduisent à une perte de fonction de la protéine. Ce gène code pour une enzyme capable de modifier les cytosines méthylées. Il participerait ainsi au contrôle de la méthylation de l'ADN et donc à la régulation épigénétique de l’expression génique. Afin de mieux comprendre son rôle au cours de l’hématopoïèse, deux modèles murins d'inactivation du gène Tet2 ont été développés. Des expériences de greffe de cellules médullaires dans des souris syngéniques montrent que les cellules déficientes pour ce gène présentent un avantage compétitif par rapport aux cellules sauvages. L’analyse des souris invalidées pour ce gène montre une amplification des populations hématopoïétiques immatures, ainsi que des anomalies de la différenciation des lignages myéloïdes et également des lignages lymphoïdes. Une fraction des souris invalidées pour Tet2 âgées de plus de six mois développe des hémopathies malignes ressemblant à la LMMC humaine. Des anomalies équivalentes sont retrouvées dans les souris hémizygotes pour Tet2 et dans des souris portant un allèle hypomorphe du gène. L’ensemble de ces résultats montre qu’une dérégulation de l'activité de Tet2 conduit à des anomalies précoces de l'hématopoïèse, mais n'entraine pas directement la transformation des cellules progénitrices immatures. La latence du développement de ces tumeurs suggère la nécessité d'une coopération avec d'autres évènements oncogéniques, comme des anomalies d’autres acteurs épigénétiques / Acquired loss-of-function mutations of TET2 gene are frequently observed in patients with myeloid malignancies, including acute myeloblastic leukemia, myeloproliferative neoplasm, myelodysplastic syndrome, and chronic myelomonocytic leukemia (CMML). The Ten-Eleven-Translocation (TET) family proteins are 2-oxoglutarate/Fe(II)-dependent dioxygenases that catalyze the conversion of 5-methyl-cytosine into 5-hydroxymethyl-cytosine, which is proposed to constitute a first step toward cytosine demethylation. To study the function of Tet2 in murine hematopoiesis, we developed two mouse models in which the catalytic domain of the protein is disrupted. In both models, Tet2 deficiency leads to the progressive expansion of the immature hematopoietic compartment that includes stem cell and multipotent progenitors. In addition, both Tet2-deficient animals display abnormalities of erythroid, megakaryocytic, myelo-monocytic and lymphoid lineages, recapitulated in competitive transplantation assays. With age, Tet2-deficient mice develop bona fide myeloid tumors. All these properties were shown to be cell-autonomous by bone marrow cells transplantation and in vitro assays. Together these data suggest that TET2 activity is essential for normal homeostasis of the hematopoietic system. Its inactivation results in the development of hematologic disorders resembling human CMML myeloid disorders. TET2 deficiency endows the cells with a competitive advantage over wild type cells, induces hematopoietic differentiation abnormalities but is not responsible for full cellular transformation. The latency observed for CMML development in mouse models of Tet2 deficiency suggests a requirement for cooperating mutations, such other epigenetic regulator alterations.
|
Page generated in 0.036 seconds